Fidelis Capital Partners, LLC Eagle Pharmaceuticals, Inc. Call Options Transaction History
Fidelis Capital Partners, LLC
- $840 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding EGRX
# of Institutions
76Shares Held
9.74MCall Options Held
1.01MPut Options Held
0-
Nantahala Capital Management, LLC New Canaan, CT1.96MShares$1.67 Million0.73% of portfolio
-
Aigh Capital Management LLC Baltimore, MD1.21MShares$1.03 Million2.46% of portfolio
-
Citigroup Inc1MShares$851,3210.0% of portfolio
-
Aqr Capital Management LLC Greenwich, CT697KShares$592,2770.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA564KShares$479,7360.0% of portfolio
About EAGLE PHARMACEUTICALS, INC.
- Ticker EGRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 13,015,900
- Market Cap $11.1M
- Description
- Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...